Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Mass campaigns with oral poliovirus vaccine (OPV) have brought the world close to the eradication of wild poliovirus. However, to complete eradication, OPV must itself be withdrawn to prevent outbreaks of vaccine-derived poliovirus (VDPV). Synchronized global withdrawal of OPV began with serotype 2 OPV (OPV2) in April 2016, which presented the first test of the feasibility of eradicating all polioviruses. METHODS: We analyzed global surveillance data on the detection of serotype 2 Sabin vaccine (Sabin-2) poliovirus and serotype 2 vaccine-derived poliovirus (VDPV2, defined as vaccine strains that are at least 0.6% divergent from Sabin-2 poliovirus in the viral protein 1 genomic region) in stool samples from 495,035 children with acute flaccid paralysis in 118 countries and in 8528 sewage samples from four countries at high risk for transmission; the samples were collected from January 1, 2013, through July 11, 2018. We used Bayesian spatiotemporal smoothing and logistic regression to identify and map risk factors for persistent detection of Sabin-2 poliovirus and VDPV2. RESULTS: The prevalence of Sabin-2 poliovirus in stool samples declined from 3.9% (95% confidence interval [CI], 3.5 to 4.3) at the time of OPV2 withdrawal to 0.2% (95% CI, 0.1 to 2.7) at 2 months after withdrawal, and the detection rate in sewage samples declined from 71.0% (95% CI, 61.0 to 80.0) to 13.0% (95% CI, 8.0 to 20.0) during the same period. However, 12 months after OPV2 withdrawal, Sabin-2 poliovirus continued to be detected in stool samples (<0.1%; 95% CI, <0.1 to 0.1) and sewage samples (8.0%; 95% CI, 5.0 to 13.0) because of the use of OPV2 in response to VDPV2 outbreaks. Nine outbreaks were reported after OPV2 withdrawal and were associated with low coverage of routine immunization (odds ratio, 1.64 [95% CI, 1.14 to 2.54] per 10% absolute decrease) and low levels of population immunity (odds ratio, 2.60 [95% CI, 1.35 to 5.59] per 10% absolute decrease) within affected countries. CONCLUSIONS: High population immunity has facilitated the decline in the prevalence of Sabin-2 poliovirus after OPV2 withdrawal and restricted the circulation of VDPV2 to areas known to be at high risk for transmission. The prevention of VDPV2 outbreaks in these known areas before the accumulation of substantial cohorts of children susceptible to type 2 poliovirus remains a high priority. (Funded by the Bill and Melinda Gates Foundation and the World Health Organization.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION
Kew, O. M., Sutter, R. W., de Gourville, E. M., Dowdle, W. R., & Pallansch, M. A. (2005) · Annual Review of Microbiology · doi:10.1146/annurev.micro.58.030603.123625 · Cited by 703
Self-citationGlobal polio eradication initiative
Koenig‐Archibugi, M. (2011) · London School of Economics and Political Science Research Online (London School of Economics and Political Science) · Cited by 523
Environmental surveillance for polioviruses in the Global Polio Eradication Initiative.
Asghar, H., Diop, O. M., Weldegebriel, G., Malik, F., Shetty, S., El Bassioni, L., Akande, A. O., Al Maamoun, E., Zaidi, S., Adeniji, A. J., et al. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu384 · Cited by 427 · cited 1×
“for the presence of polioviruses, is currently performed in over 30 countries to supplement AFP surveillance.(5,6) Here we analyse ES data from four high-risk countries in the Eastern-Mediterranean”
MethodSelf-citationVaccine Policy Changes and Epidemiology of Poliomyelitis in the United States
Alexander, L. N. (2004) · JAMA · doi:10.1001/jama.292.14.1696 · Cited by 203
Hampton, L. M., Farrell, M., Ramirez-Gonzalez, A., Menning, L., Shendale, S., Lewis, I., Rubin, J., Garon, J., Harris, J., Hyde, T., et al. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6535a3 · Cited by 193
(2012) · PubMed · Cited by 168
The Evolutionary Pathway to Virulence of an RNA Virus
Stern, A., Yeh, M. T., Zinger, T., Smith, M., Wright, C., Ling, G., Nielsen, R., Macadam, A., & Andino, R. (2017) · Cell · doi:10.1016/j.cell.2017.03.013 · Cited by 127
Apparent global interruption of wild poliovirus type 2 transmission.
(2001) · PubMed · Cited by 107
Is Polio Eradication Realistic?
Arita, I., Nakane, M., & Fenner, F. (2006) · Science · doi:10.1126/science.1124959 · Cited by 93
Modeling the Dynamics of Oral Poliovirus Vaccine Cessation
Thompson, K. M., & Tebbens, R. J. D. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit845 · Cited by 84
Huang, Q. S., Greening, G. E., Baker, M. G., Grimwood, K., Hewitt, J., Hulston, D. A., van Duin, L., Fitzsimons, A., Garrett, N., Graham, D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66386-6 · Cited by 73
Famulare, M., Chang, S., Iber, J., Zhao, K., Adeniji, J. A., Bukbuk, D., Baba, M., Behrend, M., Burns, C. C., & Oberste, M. S. (2016) · Journal of Virology · doi:10.1128/jvi.01532-15 · Cited by 73
Waning Intestinal Immunity After Vaccination With Oral Poliovirus Vaccines in India
Grassly, N. C., Jafari, H., Bahl, S., Sethi, R., Deshpande, J. M., Wolff, C., Sutter, R. W., & Aylward, R. B. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis241 · Cited by 72
Self-citationThe New Polio Eradication End Game: Rationale and Supporting Evidence
Sutter, R. W., Platt, L., Mach, O., Jafari, H. S., & Aylward, R. B. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu222 · Cited by 63
Self-citationPreventing Vaccine-Derived Poliovirus Emergence during the Polio Endgame
Pons-Salort, M., Burns, C. C., Lyons, H. M., Blake, I. M., Jafari, H. S., Oberste, M. S., Kew, O. M., & Grassly, N. C. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005728 · Cited by 60
Self-citationUpdate on Vaccine-Derived Polioviruses — Worldwide, January 2016–June 2017
Jorba, J. C., Diop, O. M., Iber, J. C., Henderson, E., Sutter, R. W., Wassilak, S. G. F., & Burns, C. C. (2017) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6643a6 · Cited by 44
Self-citationEtsano, A., Damisa, E., Shuaib, F., Nganda, G. W., Enemaku, O., Usman, S., Adeniji, A., Jorba, J., Iber, J., Ohuabunwo, C., et al. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6530a4 · Cited by 39
Surveillance systems to track progress toward global polio eradication - worldwide, 2012-2013.
Levitt, A. M., Diop, O. M., Tangermann, R. H., Paladin, F. J., Kamgang, J. B., Burns, C. C., Chenoweth, P., Goel, A., & Wassilak, S. G. F. (2014) · PubMed Central · Cited by 38
Self-citationThe risk of type 2 oral polio vaccine use in post-cessation outbreak response
McCarthy, K. A., Chabot‐Couture, G., Famulare, M., Lyons, H. M., & Mercer, L. D. (2017) · BMC Medicine · doi:10.1186/s12916-017-0937-y · Cited by 33
Alleman, M. M., Chitale, R. A., Burns, C. C., Iber, J. C., Dybdahl-Sissoko, N., Chen, Q., Koko, D.-R. V., Ewetola, R., Riziki, Y., Kavunga‐Membo, H., et al. (2018) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6710a4 · Cited by 33
Diop, O. M., Asghar, H., Gavrilin, E., Gumede, N., Rey-Benito, G. J., Paladin, F. J., Pattamadilok, S., Zhang, Y., Goel, A., & Quddus, A. (2017) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6620a4 · Cited by 31
Self-citationAdams, A. I., & SALISBURY, D. M. (2015) · Science · doi:10.1126/science.aad7294 · Cited by 25
Pons-Salort, M., Molodecky, N. A., O’Reilly, K. M., Wadood, M. Z., Safdar, R. M., Etsano, A., Vaz, R. G., Jafari, H. S., Grassly, N. C., & Blake, I. M. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002140 · Cited by 23
Self-citationFaster Detection of Poliomyelitis Outbreaks to Support Polio Eradication
Blake, I. M., Chenoweth, P., Okayasu, H., Donnelly, C. A., Aylward, R. B., & Grassly, N. C. (2016) · Emerging infectious diseases · doi:10.3201/eid2203.151394 · Cited by 22
Self-citationKroiss, S. J., Famulare, M., Lyons, H. M., McCarthy, K. A., Mercer, L. D., & Chabot‐Couture, G. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.08.048 · Cited by 11
Research works printed but not linked: 2
- Polio laboratory manual 4th edition. Geneva: World Health Organization 2004 (http://polioeradication.org/wp-content/uploads/2017/05/Polio_Lab_Manual04.pdf).
- Watanabe S. Asymptomatic equivalence of Bayes cross validation and widely applicable information criterion in singular learning theory. J Mach Learn Res 2010;11:3571-3594.
Cited by
Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence
Yeh, M. T., Bujaki, E., Dolan, P. T., Smith, M., Wahid, R., Konz, J., Weiner, A. J., Bandyopadhyay, A. S., Van Damme, P., De Coster, I., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.003 · Cited by 221
Self-citationMacklin, G. R., O’Reilly, K. M., Grassly, N. C., Edmunds, W. J., Mach, O., Santhana Gopala Krishnan, R., Voorman, A., Vertefeuille, J. F., Abdelwahab, J., Gumede, N., et al. (2020) · Science · doi:10.1126/science.aba1238 · Cited by 141
Self-citationDevelopment of a new oral poliovirus vaccine for the eradication end game using codon deoptimization
Konopka-Anstadt, J. L., Campagnoli, R., Vincent, A., Shaw, J., Wei, L., Wynn, N. T., Smithee, S. E., Bujaki, E., Te Yeh, M., Laassri, M., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-0176-7 · Cited by 96
Rosenkranz, S., Lang, I. M., Blindt, R., Bonderman, D., Bruch, L., Diller, G., Felgendreher, R., Gerges, C., Hohenforst‐Schmidt, W., Holt, S., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.08.080 · Cited by 81
Ivanova, O. E., Yarmolskaya, M. S., Eremeeva, T. P., Gm, B., Baykova, O. Y., Akhmadishina, L. V., Krasota, A. Y., Kozlovskaya, L. I., & Lukashev, A. N. (2019) · Viruses · doi:10.3390/v11050424 · Cited by 64
“It has been shown that even in absence of OPV, a substantial fraction of sewage samples (up to 8%) can contain Sabin 2 strains [28].”
Background
Metadata
- Authors
- Blake, I. M., Pons-Salort, M., Molodecky, N. A., Diop, O. M., Chenoweth, P., Bandyopadhyay, A. S., Zaffran, M., Sutter, R. W., & Grassly, N. C.
- Affiliations
- Gates Foundation (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-08-30
- Volume
- 379
- Issue
- 9
- Pages
- 834-845
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5985919
- OpenAlex
- W2889458573
- Cited by
- 79
- References
- 24
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 17 · 2020: 17 · 2019: 4 · 2018: 6
- FWCI
- 8.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion, cc-by)
- PubMed Central (acceptedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Bill and Melinda Gates Foundation (OPP1099374)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- poliovirus type 2, vaccine-derived poliovirus, polio eradication, acute flaccid paralysis surveillance, wastewater surveillance, routine immunization coverage, poliovirus outbreak
- MeSH terms
- Adolescent, Africa, Asia, Child, Child, Preschool, Disease Outbreaks, Feces, Female, Humans, Infant, Infant, Newborn, Male, Poliomyelitis, Poliovirus Vaccine, Inactivated, Poliovirus Vaccine, Oral, Population Surveillance, Sewage, Logistic Models, Poliovirus, Disease Eradication, Serogroup
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



